Last updated: 25 June 2019 at 6:09pm EST

Venture Fund Xi, L.P.Atlas ... Net Worth




The estimated Net Worth of Venture Fund Xi, L.P.Atlas ... is at least $12.9 Millón dollars as of 24 June 2019. Venture Atlas owns over 270,000 units of Akero Therapeutics Inc stock worth over $12,940,636 and over the last 5 years Venture sold AKRO stock worth over $0.

Venture Atlas AKRO stock SEC Form 4 insiders trading

Venture has made over 1 trades of the Akero Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Venture bought 270,000 units of AKRO stock worth $4,320,000 on 24 June 2019.

The largest trade Venture's ever made was buying 270,000 units of Akero Therapeutics Inc stock on 24 June 2019 worth over $4,320,000. On average, Venture trades about 270,000 units every 0 days since 2019. As of 24 June 2019 Venture still owns at least 505,099 units of Akero Therapeutics Inc stock.

You can see the complete history of Venture Atlas stock trades at the bottom of the page.



Insiders trading at Akero Therapeutics Inc

Over the last 5 years, insiders at Akero Therapeutics Inc have traded over $146,260,704 worth of Akero Therapeutics Inc stock and bought 4,870,000 units worth $104,250,550 . The most active insiders traders include Group, Llc Green Jeremy Red..., Trust Blue Horizon Enterpri... y G. Walmsley Graham. On average, Akero Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of $1,642,344. The most recent stock trade was executed by Jonathan Young on 3 September 2024, trading 5,000 units of AKRO stock currently worth $133,600.



What does Akero Therapeutics Inc do?

akero therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (nash) and other serious metabolic diseases. akero's lead clinical program, akr-001, is a long-acting fc fusion modified fgf21 protein and potential best-in-class treatment for nash. akr-001 builds upon two decades of work on fgf21 biology. it is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.



What does Akero Therapeutics Inc's logo look like?

Akero Therapeutics Inc logo

Complete history of Venture Atlas stock trades at Akero Therapeutics Inc

Fecha
#
Empresa
Persona
Trans.
Transacción
Acciones Precio por acción Precio total Acciones después de Fuente
24 Jun 2019 Venture Fund Xi, L.P.Atlas ...
Comprar 270,000 $16.00 $4,320,000
24 Jun 2019
505,099


Akero Therapeutics Inc executives and stock owners

Akero Therapeutics Inc executives and other stock owners filed with the SEC include: